CooperCompanies Financial Highlights for Fiscal Year 2025
CooperCompanies (NASDAQ: COO), a premier name in medical devices, has reported impressive financial outcomes for its fiscal year ending October 31, 2025. The company's performance showcases growth in revenue, earnings, and strategic initiatives that are poised to sustain its momentum into the next fiscal year.
Impressive Revenue Growth
The company's revenue for the fourth quarter of 2025 reached $1,065.2 million, reflecting a robust 5% increase compared to the previous year. On a full-year basis, CooperCompanies achieved total revenue of $4.1 billion, also up 5%. These results underscore the company's effective market strategies and operational efficiencies. Notably, when adjusted for currency fluctuations, the organic growth reflects an even more significant pace of 3% for the quarter and 4% on a yearly basis.
Earnings per Share (EPS) Overview
In terms of earnings, CooperCompanies reported a GAAP diluted EPS of $0.43 for the fourth quarter, a decline of 27% year-over-year. However, its non-GAAP diluted EPS increased to $1.15, marking an 11% rise. For the full year, the non-GAAP EPS stood at $4.13, witnessing a 12% increase from the previous fiscal year.
Strategic Initiatives Get Boost
Al White, the President and CEO of CooperCompanies, expressed optimism about their ongoing initiatives. He stated, "We closed fiscal 2025 ahead of consensus expectations, and we're optimistic about 2026, especially for our CooperVision segment. Product launches are set to accelerate, alongside substantial growth in our fertility business and share repurchases."
Fourth Quarter Operating Results
For the fourth quarter, CooperVision generated revenue amounting to $709.6 million, a solid 5% increase year-over-year. This segment has shown notable performance, especially with the MiSight product line, which experienced a 37% growth. CooperSurgical also reported revenues at the high end of expectations, contributing positively to the overall results.
Cash Flow & Share Buybacks
CooperCompanies also demonstrated strong cash flow management with cash provided by operations amounting to $247.8 million after capital expenditures of $98 million, yielding free cash flow of $149.8 million. The company repurchased approximately 2.9 million shares, collectively worth $197.3 million during the fourth quarter.
2026 Financial Guidance
Looking ahead, CooperCompanies has initiated guidance for the fiscal year 2026, forecasting total revenues between $4.3 billion and $4.338 billion, alongside expected non-GAAP diluted EPS between $4.45 and $4.60. This guidance reflects a continued commitment to growth and shareholder value creation.
Ongoing Optimization Efforts
During the fourth quarter, significant reorganization activities were undertaken to improve operational efficiency, with expected annual pre-tax savings of approximately $50 million starting in fiscal 2026. By leveraging technology and restructuring, CooperCompanies aims to enhance productivity and streamline costs.
CooperCompanies Overview
Founded to provide innovative solutions in the medical device industry, CooperCompanies operates through its two distinct segments—CooperVision and CooperSurgical. With a diverse product portfolio, the company is well-positioned to enhance the health and quality of life for millions globally. As a trusted name, its products are sold in over 130 countries, impacting ten million lives each day.
Frequently Asked Questions
What were the key financial results for CooperCompanies in 2025?
CooperCompanies achieved revenues of $4.1 billion for the fiscal year and a fourth-quarter revenue of $1,065.2 million, reflecting a 5% increase year-over-year.
How did the earnings per share perform for CooperCompanies?
The company reported a GAAP diluted EPS of $0.43 for the fourth quarter and a non-GAAP diluted EPS of $1.15, showcasing year-over-year growth.
What is the company's outlook for 2026?
CooperCompanies projects total revenue in the range of $4.3 billion to $4.338 billion with non-GAAP diluted EPS expected to be between $4.45 and $4.60.
How has CooperVision performed compared to CooperSurgical?
Both segments showed growth, with CooperVision's revenue reaching $709.6 million for the fourth quarter, and CooperSurgical performing strongly within guidance expectations.
What initiatives are being undertaken for operational efficiency?
The company is engaged in reorganization efforts aimed at improving operational efficiency and expects annual pre-tax savings of approximately $50 million starting in the next fiscal year.
